LBRX Company Profile and Key Details

LBRX has shown sold momentum, gaining 13.29% over the past week and 38.21% over the past quarter, though year-to-date performance is down -3.14%. Short-term trend indicators are bearishly aligned (SMA20 3.02%, SMA50 9.82%, SMA200 28.32%). The stock’s 14-day RSI is 56.06 (neutral), while the ATR of 1.48 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -5.35% below its high and over 81.36% above its low. Average 10-day trading volume of 314.76 thousand shares is slightly above the 3-month average of 263.56 thousand, indicating heightened recent market interest.

LB Pharmaceuticals Inc Common Stock (NASDAQ:LBRX) closed at $33.74 USD, losing -$0.43 (-1.26%) from the previous close of $34.17. The stock is currently within 5% of its 52-week high $13.36 and $35.34. With a market capitalization of about $967.55 million, LB Pharmaceuticals Inc Common Stock is classified as a small-cap and shows lower-than-market volatility (beta ~0.56). Key stats such as the average daily volume over the past year has been around 266.25 thousand shares, in line with its 52-week average. Headquartered in New York, NY, LB Pharmaceuticals Inc Common Stock operates in the Healthcare sector and the Biotechnology industry. Led by CEO Heather D. Turner, the company employs approximately 16 people and listed since September 11, 2025. This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression.

LB Pharmaceuticals Inc Common Stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $9.75. This means the shares are trading above this model’s fair value.

Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $78.00 to $27.00. The high target offers 131.18% upside. The low target suggests -19.98% downside. The mean target is $42.50. This offers 25.96% upside. LB Pharmaceuticals Inc Common Stock earnings surprise history is a mixed track record. The quarter that ended May 12, 2026, missed forecasts by -10.67%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include 7.02% in November 06, 2025.

LB Pharmaceuticals Inc Common Stock (NASDAQ:LBRX) shares are flat -3.14% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows LB Pharmaceuticals Inc Common Stock trading at a premium to the broader market with a P/E of -1.56. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $42.50, suggesting 25.96% upside. Our AI forecast model points to short-term strength (11.11% over two weeks), a medium-term rise (47.51% over three months), and a longer-term gain (60.97% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that LB Pharmaceuticals Inc Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 11.11%, with price expected at $37.49 by July 22, 2026, within a range of $36.68 to $38.19 3-Month Outlook: Projected rise of 47.51%, reaching $49.77 by October 06, 2026, with a range of $49.46 to $50.13. 1-Year Outlook: Projected gain of 60.97%, with price at $54.31 by July 08, 2027, within a range of $53.85 to $54.77.

LB Pharmaceuticals Inc Common Stock trades at a P/E ratio of -1.56, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.49 suggesting the stock is closer to book value. The P/FCF stands at -19.01, also above market averages.